07:09 AM EDT, 10/07/2025 (MT Newswires) -- Merck ( MRK ) said Tuesday it has completed its $10 billion acquisition of Verona Pharma ( VRNA ) .
Verona Pharma ( VRNA ) is no longer listed or traded on Nasdaq and becomes a wholly owned Merck ( MRK ) subsidiary, the company said.
The acquisition is expected to negatively impact its non-GAAP earnings per share by around $0.16 in the first 12 months, Merck ( MRK ) said.